EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exosome‐related lncRNA score: A value‐based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma

Zhan Yang, Xiaoting Zhang, Ning Zhan, Lining Lin, Jingyu Zhang, Lianjie Peng, Tao Qiu, Yaxian Luo, Chundi Liu, Chaoran Pan, Junhao Hu, Yifan Ye und 4 weitere

Cancer Medicine · 2024-06 · 13 (11)

DOI: 10.1002/cam4.7308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 29.05.2024. Verfasst von Zhan Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, RNA, Long Noncoding, Kidney Neoplasms, Exosomes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, Zhejiang University of Stomatology Postdoctoral Scientific Research Foundation, Zhejiang Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Exosomes play a crucial role in intercellular communication in clear cell renal cell carcinoma (ccRCC), while the long non‐coding RNAs (lncRNAs) are implicated in tumorigenesis and progression.

Aims

The purpose of this study is to construction a exosomes‐related lncRNA score and a ceRNA network to predict the response to immunotherapy and potential targeted drug in ccRCC.

Methods

Data of ccRCC patients were obtained from the TCGA database. Pearson correlation analysis was used to identify eExosomes‐related lncRNAs (ERLRs) from Top10 exosomes‐related genes that have been screened. The entire cohort was randomly divided into a training cohort and a validation cohort in equal scale. LASSO regression and multivariate cox regression was used to construct the ERLRs‐based score. Differences in clinicopathological characteristics, immune microenvironment, immune checkpoints, and drug susceptibility between the high‐ and low‐risk groups were also investigated. Finally, the relevant ceRNA network was constructed by machine learning to analyze their potential targets in immunotherapy and drug use of ccRCC patients.

Results

A score consisting of 4ERLRs was identified, and patients with higher ERLRs‐based score tended to have a worse prognosis than those with lower ERLRs‐based score. ROC curves and multivariate Cox regression analysis demonstrated that the score could be considered as a risk factor for prognosis in both training and validation cohorts. Moreover, patients with high scores are predisposed to experience poor overall survival, a larger prevalence of advanced stage (III‐IV), a greater tumor mutational burden, a higher infiltration of immunosuppressive cells, and a greater likelihood of responding favorably to immunotherapy. The importance of EMX2OS was determined by mechanical learning, and the ceRNA network was constructed, and EMX2OS may be a potential therapeutic target, possibly exerting its function through the EMX2OS/hsa‐miR‐31‐5p/TLN2 axis.

Conclusions

Based on machine learning, a novel ERLRs‐based score was constructed for predicting the survival of ccRCC patients. The ERLRs‐based score is a promising potential independent prognostic factor that is closely correlated with the immune microenvironment and clinicopathological characteristics. Meanwhile, we screened out key lncRNAEMX2OS and identified the EMX2OS/hsa‐miR‐31‐5p/TLN2 axis, which may provide new clues for the targeted therapy of ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellRNA, Long NoncodingKidney NeoplasmsExosomesImmunotherapyHumansMaleFemaleMiddle AgedPrognosisTumor MicroenvironmentBiomarkers, TumorGene Expression Regulation, NeoplasticGene Regulatory Networks

Stichwörter der Autor:innen

ceRNA networkclear cell renal cell carcinomaexosomelncRNAmachine learningprecision medicinetumor microenvironment

Substanzen

RNA, Long NoncodingBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
  • Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cance…

ORCID-Profile: Mouyuan Sun

Förderung

  • China Postdoctoral Science Foundation
  • Zhejiang University of Stomatology Postdoctoral Scientific Research Foundation
  • Zhejiang Provincial Natural Science Foundation of China

Zitieren

APA

Yang, Z., Zhang, X., Zhan, N., Lin, L., Zhang, J., Peng, L., Qiu, T., Luo, Y., Liu, C., Pan, C., Hu, J., Ye, Y., Jiang, Z., Liu, X., Sun, M., & Zhang, Y. (2024). Exosome‐related lncRNA score: A value‐based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma. Cancer Medicine, 13(11). https://doi.org/10.1002/cam4.7308

Vancouver

Yang Z, Zhang X, Zhan N, Lin L, Zhang J, Peng L, et al. Exosome‐related lncRNA score: A value‐based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma. Cancer Medicine. 2024;13(11). doi:10.1002/cam4.7308

BibTeX
@article{Yang2024,
  author = {Yang, Zhan and Zhang, Xiaoting and Zhan, Ning and Lin, Lining and Zhang, Jingyu and Peng, Lianjie and Qiu, Tao and Luo, Yaxian and Liu, Chundi and Pan, Chaoran and Hu, Junhao and Ye, Yifan and Jiang, Zilong and Liu, Xinyu and Sun, Mouyuan and Zhang, Yan},
  title = {Exosome‐related lncRNA score: A value‐based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {11},
  doi = {10.1002/cam4.7308}
}
Kostenlos starten →